Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics

  1. Carmen Capone
  2. Fabrice Dabertrand
  3. Celine Baron-Menguy
  4. Athena Chalaris
  5. Lamia Ghezali
  6. Valérie Domenga-Denier
  7. Stefanie Schmidt
  8. Clément Huneau
  9. Stefan Rose-John
  10. Mark T Nelson
  11. Anne Joutel  Is a corresponding author
  1. INSERM, France
  2. University of Vermont, United States
  3. Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Germany
  4. University of Vermont, University of Manchester, United States

Abstract

Cerebral small vessel disease (SVD) is a leading cause of stroke and dementia. CADASIL, an inherited SVD, alters cerebral artery function, compromising blood flow to the working brain. TIMP3 (tissue inhibitor of metalloproteinase 3) accumulation in the vascular extracellular matrix in CADASIL is a key contributor to cerebrovascular dysfunction. However, the linkage between elevated TIMP3 and compromised cerebral blood flow (CBF) remains unknown. Here, we show that TIMP3 acts through inhibition of the metalloprotease ADAM17 and HB-EGF to regulate cerebral arterial tone and blood flow responses. In a clinically relevant CADASIL mouse model, we show that exogenous ADAM17 or HB-EGF restores cerebral arterial tone and blood flow responses, and identify upregulated voltage-dependent potassium channel (KV) number in cerebral arterial myocytes as a heretofore-unrecognized downstream effector of TIMP3-induced deficits. These results support the concept that the balance of TIMP3 and ADAM17 activity modulates CBF through regulation of myocyte KV channel number.

Article and author information

Author details

  1. Carmen Capone

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Fabrice Dabertrand

    Department of Pharmacology, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Celine Baron-Menguy

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Athena Chalaris

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Lamia Ghezali

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Valérie Domenga-Denier

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Stefanie Schmidt

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Clément Huneau

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Stefan Rose-John

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Mark T Nelson

    Department of Pharmacology, University of Vermont, University of Manchester, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Anne Joutel

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    For correspondence
    anne.joutel@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3963-3860

Funding

Agence Nationale de la Recherche (ANR Genopath 2009-RAE09011HSA and ANR Blanc 2010-RPV11011HHA)

  • Anne Joutel

Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain)

  • Mark T Nelson
  • Anne Joutel

European Union (Horizon 2020 research and innovation programme SVDs@target, grant agreement No 666881)

  • Mark T Nelson
  • Anne Joutel

National Institute of Health (R37DK053832, PO1HL095488, RO1HL44455, R01HL121706, R01HL131181)

  • Mark T Nelson

Totman Medical Research Trust

  • Mark T Nelson

United Leukodystrophy Foundation (CADASIL Research Grant)

  • Fabrice Dabertrand

Deutsche Forschungsgemeinschaft (DFG, SFB877 project A1 and the Cluster of Excellence Inflammation at Interfaces)

  • Athena Chalaris
  • Stefan Rose-John

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. David E Clapham, Howard Hughes Medical Institute, Boston Children's Hospital, United States

Ethics

Animal experimentation: All experiments were conducted in full accordance with the French guidelines for the use of animals in research and were approved by the "Lariboisière-Villemin" Institutional Animal Care and Use Committee (C2EA 09), with every effort made to minimize the number of animals used.

Version history

  1. Received: May 5, 2016
  2. Accepted: July 30, 2016
  3. Accepted Manuscript published: August 1, 2016 (version 1)
  4. Version of Record published: August 22, 2016 (version 2)

Copyright

© 2016, Capone et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,800
    Page views
  • 425
    Downloads
  • 55
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carmen Capone
  2. Fabrice Dabertrand
  3. Celine Baron-Menguy
  4. Athena Chalaris
  5. Lamia Ghezali
  6. Valérie Domenga-Denier
  7. Stefanie Schmidt
  8. Clément Huneau
  9. Stefan Rose-John
  10. Mark T Nelson
  11. Anne Joutel
(2016)
Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics
eLife 5:e17536.
https://doi.org/10.7554/eLife.17536

Share this article

https://doi.org/10.7554/eLife.17536

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.